Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study
Joseph J. Eron(University of North Carolina at Chapel Hill), Marina Caskey(Rockefeller University), Susan J. Little(University of California San Diego), Laurie A. VanderVeen(Gilead Sciences (United States)), Anthony Mills(Oncotherapeutics (United States)), Jared M. Baeten(University of Washington), Moti Ramgopal(Midway University), Dushyantha Jayaweera(University of Miami), Linda Gorgos, Peter Ruane, Sarah Waldman(University of California, Davis), Gordon Crofoot(Clinical Research Organization), Yanan Zheng(Gilead Sciences (United States)), Edwin DeJesus(Orlando Immunology Center), Sean E Collins(Gilead Sciences (United States)), Paul Cook(East Carolina University), Hailin Huang(University of Electronic Science and Technology of China)
Cited by 47
Related Papers
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
|Nature Medicine|2002|1.6k
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by <i>Staphylococcus aureus</i>
|New England Journal of Medicine|2006|1.5k
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
|Proceedings of the National Academy of Sciences|2003|1.2k
Antiretroviral-Drug Resistance among Patients Recently Infected with HIV
|New England Journal of Medicine|2002|1.1k